Pelthos <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports $7.4 million in third quarter revenue
Pelthos Therapeutics Inc. reported total revenue of $7.4 million for the third quarter ended September 30, 2025, compared to no revenue in the same period of 2024. Net product revenues from the commercial launch of ZELSUVMI, its FDA-approved at-home treatment for molluscum contagiosum, were $7.1 million, while license and collaboration revenues were $0.3 million. The company reported a net loss of $16.2 million, or $5.30 per basic and fully diluted common share. Cash and cash equivalents increased to $14.2 million as of September 30, 2025, from $0.5 million at the end of 2024, following a $50.1 million equity private placement. During the quarter, 2,716 units of ZELSUVMI were dispensed by 1,169 unique prescribers. The merger of Channel Therapeutics Corporation and LNHC, Inc. was completed to form Pelthos Therapeutics.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001753926-25-001766), on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.